Many patients with lung adenocarcinoma (LUAD), a major subtype of lung cancer [2], harbor mutations in the epidermal growth factor receptor (EGFR) in their cancer tissues and initially react well to molecular targeted drugs such as gefitinib, which inhibits EGFR tyrosine kinase (TKI) [3, 4]. The gene discussed is EGFR; the disease is lung cancer.